

DAFTAR PUSTAKA

- Amalia, A., Latief, N., Murtala, B., Zainuddin, A. A., & Daud, N. A. (2020). Factors affecting tumor response to transarterial chemoembolization (TACE) therapy in patient with hepatocellular carcinoma (HCC). *Journal of the Medical Sciences (Berkala Ilmu Kedokteran)*, 52(02), 144–152.
- Barghini, Valerio; Donnini, Debora; Uzzao, Alessandro; Soardo, G. (2013). Sign and Symptoms of Hepatocellular Carcinoma. *Hepatocellular Carcinoma : Future Outlook*, 197–202.
- Basile, A., Carrafiello, G., Ierardi, A. M., Tsetis, D., & Brountzos, E. (2012). Quality-improvement guidelines for hepatic transarterial chemoembolization. *CardioVascular and Interventional Radiology*, 35(4), 765–774.
- Bryant, M. K., Dorn, D. P., Zarzour, J., Smith, J. K., Redden, D. T., Saddekni, S., Aal, A. K. A., Gray, S. H., Eckhoff, D. E., & Dubay, D. A. (2014). Computed tomography predictors of hepatocellular carcinoma tumour necrosis after chemoembolization. *Hpb*, 16(4), 327–335.
- Budjan, J., Sauter, E. A., Morelli, J. N., Nolden, M., Fetzer, A., Pilz, L., Reichert, M., Brandt, T., Hansmann, J., Haneder, S., Rathmann, N., Diehl, S. J., Meinzer, H. P., Schoenberg, S. O., & Attenberger, U. I. (2016). Semi-automatic volumetric measurement of treatment response in hepatocellular carcinoma after trans-arterial chemoembolization. *Anticancer Research*, 36(8), 4353–4358.
- Cartier, V., & Aubé, C. (2014). Diagnosis of hepatocellular carcinoma. *Diagnostic and Interventional Imaging*, 95(7–8), 709–719.
- Cerny, M., Chernyak, V., Olivié, D., Murphy-lavallée, J., Kielar, A. Z., Elsayes, K. M., Bourque, L., Hooker, J. C., & Sirlin, C. B. (2018). *LI-RADS Version 2018 Ancillary Features at MRI*. 11.
- Choi, M. H., Park, G. E., Oh, S. N., Park, M. Y., Rha, S. E., Lee, Y. J., Jung, S. E., & Choi, J. Il. (2018). Reproducibility of mRECIST in Measurement and Response

- Assessment for Hepatocellular Carcinoma Treated by Transarterial Chemoembolization. *Academic Radiology*, 25(11), 1363–1373.
- Dasgupta, P., Henshaw, C., Youlden, D. R., Clark, P. J., Aitken, J. F., & Baade, P. D. (2020). Global Trends in Incidence Rates of Primary Adult Liver Cancers: A Systematic Review and Meta-Analysis. *Frontiers in Oncology*.
- Delli Pizzi, A., Mastrodicasa, D., Cianci, R., Serafini, F. L., Mincuzzi, E., Di Fabio, F., Giammarino, A., Mannetta, G., Basilico, R., & Caulo, M. (2020). Multimodality Imaging of Hepatocellular Carcinoma: From Diagnosis to Treatment Response Assessment in Everyday Clinical Practice. *Canadian Association of Radiologists Journal*.
- Di Bisceglie, A. M. (2002). Epidemiology and clinical presentation of hepatocellular carcinoma. *Journal of Vascular and Interventional Radiology*, 13(9 II), 169–171.
- Dioguardi Burgio, M., Sartoris, R., Libotean, C., Zappa, M., Sibert, A., Vilgrain, V., & Ronot, M. (2019). Lipiodol retention pattern after TACE for HCC is a predictor for local progression in lesions with complete response. *Cancer Imaging*, 19(1), 1–9.
- Ellis, H. (2011). Anatomy of the liver. *Surgery*, 29(12), 589–592.
- Ellis, J. A., Banu, M., Hossain, S. S., Singh-Moon, R., Lavine, S. D., Bruce, J. N., & Joshi, S. (2015). Reassessing the Role of Intra-Arterial Drug Delivery for Glioblastoma Multiforme Treatment. *Journal of Drug Delivery*, 2015, 1–15.
- Elsayes, K. M., Kielar, A. Z., Chernyak, V., Morshid, A., Furlan, A., Masch, W. R., Marks, R. M., Kamaya, A., Do, R. K., Kono, Y., Fowler, K. J., Tang, A., Bashir, M. R., Hecht, E. M., Jambhekar, K., Lyshchik, A., Rodgers, S. K., Heiken, J. P., Kohli, M., ... Sirlin, C. B. (2019). LI-RADS: a conceptual and historical review from its beginning to its recent integration into AASLD clinical practice guidance. *Journal of Hepatocellular Carcinoma*, Volume 6, 49–69.
- Encyclopaedia Britannica. (n.d.). *Liver / anatomy / Britannica*. Retrieved January 26, 2022, from <https://www.britannica.com/science/liver>
- Fendler, W. P., Lechner, H., Todica, A., Paprottka, K. J., Paprottka, P. M., Jakobs, T.

- F., Michl, M., Bartenstein, P., Lehner, S., & Haug, A. R. (2016). Safety, efficacy, and prognostic factors after radioembolization of hepatic metastases from breast cancer: A large single-center experience in 81 patients. *Journal of Nuclear Medicine*, 57(4), 517–523.
- Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J. L., Schirmacher, P., & Vilgrain, V. (2018). EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. *Journal of Hepatology*, 69(1), 182–236.
- Giannitrapani, L., Zerbo, M., Amodeo, S., Pipitone, E., Galia, M., Li Cavoli, T. V., Minissale, M. G., Licata, A., Schiavone, C., Brancatelli, G., Montalto, G., Soresi, M., & Galati, L. (2020). The Changing Epidemiology of Hepatocellular Carcinoma: Experience of a Single Center. *BioMed Research International*.
- Gonzalez-Guindalini, F. D., Botelho, M. P. F., Harmath, C. B., Sandrasegaran, K., Miller, F. H., Salem, R., & Yaghamai, V. (2013). Assessment of liver tumor response to therapy: Role of quantitative imaging. *Radiographics*, 33(6), 1781–1800.
- Grandhi, M. S., Kim, A. K., Ronnekleiv-Kelly, S. M., Kamel, I. R., Ghasebeh, M. A., & Pawlik, T. M. (2016). Hepatocellular carcinoma: From diagnosis to treatment. *Surgical Oncology*, 25(2), 74–85.
- Hyun, D., Shin, S. W., Cho, S. K., Park, K. B., Park, H. S., Choo, S. W., Do, Y. S., Choo, I. W., Shin, J. W., & Lim, S. J. (2015). Efficacy of RECIST and mRECIST criteria as prognostic factors in patients undergoing repeated iodized oil chemoembolization of intermediate stage hepatocellular carcinoma. *Acta Radiologica*, 56(12), 1437–1445.
- Idée, J. M., & Guiu, B. (2013). Use of Lipiodol as a drug-delivery system for transcatheter arterial chemoembolization of hepatocellular carcinoma: A review. *Critical Reviews in Oncology/Hematology*, 88(3), 530–549.
- International Agency For Research on Cancer. (2020). Cancer Case in Indonesia 2020. *The Global Cancer Observatory*, 1–2.

- Kim, T. M., Lee, J. M., Yoon, J. H., Joo, I., Park, S. J., Jeon, S. K., Schmidt, B., & Martin, S. (2020). Prediction of microvascular invasion of hepatocellular carcinoma: Value of volumetric iodine quantification using preoperative dual-energy computed tomography. *Cancer Imaging*, 20(1), 1–11.
- Lencioni, R., & Crocetti, L. (2012). Local-regional treatment of hepatocellular carcinoma. *Radiology*, 262(1), 43–58.
- Lencioni, R., de Baere, T., Soulen, M. C., Rilling, W. S., & Geschwind, J. F. H. (2016). Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data. *Hepatology*, 64(1), 106–116.
- Lim, M. C., Tan, C. H., Cai, J., Zheng, J., & Kow, A. W. C. (2014). CT volumetry of the liver: Where does it stand in clinical practice? *Clinical Radiology*, 69(9), 887–895.
- Ling Khoo, T. S. W., Rehman, A., & Olynyk, J. K. (2019). Tyrosine Kinase Inhibitors in the Treatment of Hepatocellular Carcinoma. In *Hepatocellular Carcinoma* (pp. 127–139). Codon Publications.
- Liu, L., Wang, W., Chen, H., Zhao, Y., Bai, W., Yin, Z., He, C., Jia, J., Yang, M., Xia, J., Fan, D., & Han, G. (2014). EASL- and mRECIST-Evaluated Responses to Combination Therapy of Sorafenib with Transarterial Chemoembolization Predict Survival in Patients with Hepatocellular Carcinoma. *Clinical Cancer Research*, 20(6), 1623–1631.
- Llovet, J. M., & Lencioni, R. (2020). mRECIST for HCC: Performance and novel refinements. *Journal of Hepatology*, 72(2), 288–306.
- Mahadevan, A., Blanck, O., Lanciano, R., Peddada, A., Sundararaman, S., D'Ambrosio, D., Sharma, S., Perry, D., Kolker, J., & Davis, J. (2018). Stereotactic Body Radiotherapy (SBRT) for liver metastasis - clinical outcomes from the international multi-institutional RSSearch® Patient Registry. *Radiation Oncology (London, England)*, 13(1).
- Mandrekar, J. N. (2011). Measures of interrater agreement. *Journal of Thoracic Oncology*, 6(1), 6–7.

- Memon, K., Lewandowski, R. J., Kulik, L., Riaz, A., Mulcahy, M. F., & Salem, R. (2011). Radioembolization for Primary and Metastatic Liver Cancer. *Seminars in Radiation Oncology*, 21(4), 294–302.
- Meng, M., Li, W., Yang, X., Huang, G., Wei, Z., Ni, Y., Han, X., Wang, J., & Ye, X. (2020). Transarterial chemoembolization, ablation, tyrosine kinase inhibitors, and immunotherapy (TATI): A novel treatment for patients with advanced hepatocellular carcinoma. *Journal of Cancer Research and Therapeutics*, 16(2), 327.
- Miki, I., Murata, S., Uchiyama, F., Yasui, D., Ueda, T., Sugihara, F., Saito, H., Yamaguchi, H., Murakami, R., Kawamoto, C., Uchida, E., & Kumita, S. I. (2017). Evaluation of the relationship between hepatocellular carcinoma location and transarterial chemoembolization efficacy. *World Journal of Gastroenterology*, 23(35), 6437–6447.
- Mittal, S., & El-Serag, H. B. (2013). Epidemiology of Hepatocellular Carcinoma. *Journal Clinical Gastroenterology*, 73(S1), 4–13.
- Miyayama, S. (2011). Applying Superselective Conventional TACE - Endovascular Today. *CardioVascular and Interventional Radiology*, 34(6), 1244–1253.
- Moawad, A. W., Fuentes, D., Khalaf, A. M., Blair, K. J., Szklaruk, J., Qayyum, A., Hazle, J. D., & Elsayes, K. M. (2020). Feasibility of Automated Volumetric Assessment of Large Hepatocellular Carcinomas' Responses to Transarterial Chemoembolization. *Frontiers in Oncology*, 10, 572.
- Mohammadian, M., Mahdavifar, N., Mohammadian-Hafshejani, A., & Salehiniya, H. (2018). Liver cancer in the world: epidemiology, incidence, mortality and risk factors. *World Cancer Research Journal*, 5(2), e1082.
- Narsinh, K. H., Duncan, D. P., Newton, I. G., Minocha, J., & Rose, S. C. (2018). Liver-directed therapy for hepatocellular carcinoma. *Abdominal Radiology*, 43(1), 203–217.
- Nouri, Y. M., Kim, J. H., Yoon, H. K., Ko, H. K., Shin, J. H., & Gwon, D. Il. (2019). Update on transarterial chemoembolization with drug-eluting microspheres for

- hepatocellular carcinoma. *Korean Journal of Radiology*, 20(1), 34–49.
- Osman, M. F., Farag, A. S. A., Samy, H. A., El-Baz, T. M., & Elkholy, S. F. (2021). Role of multislice computed tomography 3D volumetric analysis in the assessment of the therapeutic response of hepatocellular carcinoma after transarterial chemoembolization. *Egyptian Journal of Radiology and Nuclear Medicine*, 52(1).
- P. Tushar, D. H. (2014). Assessment of response to therapy in Hepatocellular Carcinoma. *National Institute of Health*, 46(3), 130–137.
- Piscaglia, F., & Ogasawara, S. (2018). Patient Selection for Transarterial Chemoembolization in Hepatocellular Carcinoma: Importance of Benefit/Risk Assessment. *Liver Cancer*, 7(1), 104–119.
- Pupulim, L. F., Ronot, M., Paradis, V., Chemouny, S., & Vilgrain, V. (2018). Volumetric measurement of hepatic tumors: Accuracy of manual contouring using CT with volumetric pathology as the reference method. *Diagnostic and Interventional Imaging*, 99(2), 83–89.
- Raoul, J., Forner, A., Bolondi, L., To, T., & Kloeckner, R. (2019). Updated use of TACE for hepatocellular carcinoma treatment : How and when to use it based on clinical evidence. *Cancer Treatment Reviews*, 72(August 2018), 28–36.
- Ronot, M., Bouattour, M., Wassermann, J., Bruno, O., Dreyer, C., Larroque, B., Castera, L., Vilgrain, V., Belghiti, J., Raymond, E., & Faivre, S. (2014). Alternative Response Criteria (Choi, European Association for the Study of the Liver, and Modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in Patients With Advanced Hepatocellular Carcinoma Treated With Sorafenib. *The Oncologist*, 19(4), 394–402.
- Santillan, C., Fowler, K., Kono, Y., & Chernyak, V. (2018). LI-RADS major features: CT, MRI with extracellular agents, and MRI with hepatobiliary agents. *Abdominal Radiology*.
- Sato, Y., Watanabe, H., Sone, M., Onaya, H., Sakamoto, N., Osuga, K., Takahashi, M., & Arai, Y. (2013). Tumor response evaluation criteria for HCC (hepatocellular

- carcinoma) treated using TACE (transcatheter arterial chemoembolization): RECIST (response evaluation criteria in solid tumors) version 1.1 and mRECIST (modified RECIST): JIVROSG-0602. *Upsala Journal of Medical Sciences*, 118(1), 16–22.
- Shao, Y. Y., Huang, C. C., Liang, P. C., & Lin, Z. Z. (2010). Hepatic arterial infusion of chemotherapy for advanced hepatocellular carcinoma. *Asia-Pacific Journal of Clinical Oncology*, 6(2), 80–88.
- Sibulesky, L. (2013). Normal liver anatomy. In *Clinical Liver Disease*.
- Sieghart, W., Huckle, F., & Peck-Radosavljevic, M. (2015). Transarterial chemoembolization: modalities, indication, and patient selection. *Journal of Hepatology*, 62(5), 1187–1195.
- Singal, A. G., Lampertico, P., & Nahon, P. (2020). Epidemiology and surveillance for hepatocellular carcinoma: New trends. In *Journal of Hepatology*.
- Spach, D. (n.d.). *Core Concepts - Treatment of HCV in Persons with Cirrhosis - Treatment of Key Populations and Unique Situations - Hepatitis C Online*. Hepatitis C Online. Retrieved January 28, 2022, from <https://www.hepatitisc.uw.edu/go/key-populations-situations/treatment>
- Spieler, B., Sabottke, C., Moawad, A. W., Gabr, A. M., Bashir, M. R., Do, R. K. G., Yaghmai, V., Rozenberg, R., Gerena, M., Yacoub, J., & Elsayes, K. M. (2021). Artificial intelligence in assessment of hepatocellular carcinoma treatment response. *Abdominal Radiology*, 46(8), 3660–3671.
- Tacher, V., Lin, M. De, Duran, R., Yarmohammadi, H., Lee, H., Chapiro, J., Chao, M., Wang, Z., Frangakis, C., Sohn, J. H., Maltenfort, M. G., Pawlik, T., & Geschwind, J. F. (2016). Comparison of existing response criteria in patients with hepatocellular carcinoma treated with transarterial chemoembolization using a 3D quantitative approach. *Radiology*, 278(1), 275–284.
- Tang, A., Hallouch, O., Chernyak, V., Kamaya, A., & Sirlin, C. B. (2018). Epidemiology of hepatocellular carcinoma: target population for surveillance and diagnosis. In *Abdominal Radiology*.

- The Global Cancer Observatory. (2020). Cancer Incident in Indonesia. *International Agency for Research on Cancer*, 858, 1–2.
- Timaran Montenegro, D. E., Torres Ramirez, C. A., Mateo C, Y. S., Govea Palma, J., Quiñones, J. C., & Orozco Vazquez, J. S. (2020). CT-Based Hepatic Residual Volume and Predictors of Outcomes of Patients with Hepatocellular Carcinoma Unsuitable for Surgical Therapy Undergoing Transarterial Chemoembolization. *Academic Radiology*, 27(6), 807–814.
- Torres, M. C. P., Bodini, G., Furnari, M., Marabotto, E., Zentilin, P., Strazzabosco, M., & Giannini, E. G. (2020). Surveillance for hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: Universal or selective? *Cancers*, 12(6).
- Varzaneh, F., Pandey, A., Ghasabeh, M., Shao, N., Koshpouri, P., Pandey, P., Zarghampour, M., Fouladi, D., Liddel, R., Anders, R., & Kamel, I. (2018). Prediction of post-TACE necrosis of hepatocellular carcinoma using volumetric enhancement on MRI and volumetric oil deposition on CT, with pathological correlation. *European Radiology*, 28(7), 3032–3040.
- Vesselle, G., Quirier-leleu, C., Velasco, S., Charier, F., Silvain, C., Boucebc, S., Ingrand, P., & Tasu, J. (2015). Predictive factors for complete response of chemoembolization with drug-eluting beads (DEB-TACE) for hepatocellular carcinoma. *European Radiology*, 10, 1–9.
- West, H., & Jin, J. O. (2015). Transarterial Chemoembolization. *JAMA Oncology*, 1(8), 1178–1178.
- Yeo, D. M., Choi, J. Il, Lee, Y. J., Park, M. Y., Chun, H. J., & Lee, H. G. (2014). Comparison of RECIST, mRECIST, and choi criteria for early response evaluation of hepatocellular carcinoma after transarterial chemoembolization using drug-eluting beads. *Journal of Computer Assisted Tomography*, 38(3), 391–397.
- Zhang, J. W., Feng, X. Y., Liu, H. Q., Yao, Z. W., Yang, Y. M., Liu, B., & Yu, Y. Q. (2010). CT volume measurement for prognostic evaluation of unresectable hepatocellular carcinoma after TACE. *World Journal of Gastroenterology*,

16(16), 2038–2045.